OLD Category: signatures

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

• Davies A et al.,

The Phenotypic Effects of Exosomes Secreted from Distinct Cellular Sources: A Comparative Study based on miRNA Composition

• Ferguson S et al.,

Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme

• Zhang B et al.,

Lipopolysaccharide inhalation recruits monocytes and dendritic cell subsets to the alveolar airspace

• Jardine L et al.,

Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia

• Wingo TS et al.,

Safety and Tolerability of Bacteriophage Therapy in Severe Staphylococcus aureus Infection

• Fabijan AP et al.,

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

• Butterfield LH et al.,

Composed endotypes to guide antibiotic discontinuation in sepsis

• Bermejo-Martin JF et al.,

Genetic screens reveal mechanisms for the transcriptional regulation of tissue-specific genes in normal cells and tumors

• Naciri I. et al.,

Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis

• Hicks ND et al.,

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer

• Ryu J.-S. et al.,

Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

• Pallocca M et al.,